written on 06.05.2014

AstraZeneca unveils rosy forecast to persuade investors it's better off alone


Now, it's AstraZeneca's turn to tick off all the reasons why it shouldn't sell to Pfizer. Between new plans for existing products and its prospects for new ones, AstraZeneca says it will boost sales to $45 billion by 2023–about $20 billion higher than they are now.